AbbVie's (ABBV) Allergan Unit Wins FDA Approval for SKINVIVE Neck Injectable

Allergan Aesthetics, a division of AbbVie Inc. (NYSE: ABBV), received U.S. Food and Drug Administration approval on June 16, 2026, to expand SKINVIVE's indication to improve neck skin appearance. The hyaluronic acid-based injectable becomes the first FDA-cleared treatment specifically targeting neck aesthetics through dermal hydration. SKINVIVE, initially approved for facial skin smoothness in 2023, uses microdroplet injection technology to enhance skin quality for up to six months. The neck indication addresses a significant aesthetic medicine gap, as the neck area typically shows visible signs of aging but has limited non-surgical treatment options. Allergan did not disclose clinical trial data or commercialization timelines in the announcement. The approval strengthens AbbVie's aesthetics portfolio, which generated $5.7 billion in revenue in 2025. Allergan competes with Galderma, Merz Pharma, and Revance Therapeutics in the $15 billion global aesthetic injectables market.